31-10-2024 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
36,860 |
2.80 |
2.69 |
2.53 |
IDEXX Laboratories Non-GAAP EPS of $2.79 beats by $0.10, revenue of $975.54M misses by $5.42M [10/31/2024 6:32 AM] |
408.83 |
-42.25 (-9.37%) |
433.56 |
-17.52 (-3.88%) |
372.50 - 583.39 |
1,765,729 |
690,000 |
841 |
|
|
06-08-2024 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
39,460 |
2.44 |
2.87 |
2.67 |
IDEXX Laboratories beats top-line and bottom-line estimates; narrows FY24 outlook [8/6/2024 6:33 AM] |
469.37 |
14.29 (3.14%) |
469.37 |
0.0 (0.00%) |
372.50 - 583.39 |
1,072,060 |
660,000 |
5,494 |
|
|
01-05-2024 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
41,990 |
2.81 |
2.68 |
2.55 |
IDEXX Laboratories reports mixed Q1 results; updates FY24 outlook [5/1/2024 6:33 AM] |
468.54 |
-24.22 (-4.92%) |
492.76 |
0.0 (0.00%) |
372.50 - 583.39 |
836,760 |
500,000 |
2,194 |
|
|
05-02-2024 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
43,790 |
2.32 |
2.12 |
2.05 |
IDEXX Laboratories beats top-line and bottom-line estimates; initiates FY24 outlook [2/5/2024 6:34 AM] |
572.70 |
45.56 (8.64%) |
530.00 |
2.86 (0.54%) |
372.50 - 573.62 |
777,647 |
410,000 |
7,639 |
|
|
01-11-2023 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
32,910 |
2.53 |
2.37 |
2.15 |
IDEXX Laboratories GAAP EPS of $2.53 beats by $0.16, revenue of $916M misses by $11.31M [11/1/2023 6:36 AM] |
395.06 |
-4.41 (-1.10%) |
375.00 |
-24.47 (-6.13%) |
354.81 - 564.73 |
1,303,247 |
510,000 |
1,972 |
|
|
01-08-2023 |
PM |
|
IDXX |
IDEXX Laboratories, Inc. |
45,880 |
2.67 |
2.43 |
1.56 |
IDEXX Laboratories Non-GAAP EPS of $2.70 beats by $0.23, revenue of $943.63M beats by $9.58M [8/1/2023 6:33 AM] |
532.18 |
-22.55 (-4.07%) |
543.00 |
-11.73 (-2.11%) |
317.06 - 564.73 |
556,634 |
550,000 |
2,172 |
|
|
02-05-2023 |
PM |
6:30 AM ET (May 2) |
IDXX |
IDEXX Laboratories, Inc. |
40,210 |
2.55 |
2.39 |
2.27 |
IDEXX Laboratories GAAP EPS of $2.55 beats by $0.17, revenue of $900M beats by $9.4M [5/2/2023 6:33 AM] |
467.46 |
-22.14 (-4.52%) |
482.00 |
-7.60 (-1.55%) |
317.06 - 515.79 |
526,607 |
350,000 |
1,993 |
|
|
06-02-2023 |
PM |
6:30 AM ET (Feb 6) |
IDXX |
IDEXX Laboratories, Inc. |
41,760 |
2.05 |
1.92 |
1.89 |
IDEXX Laboratories Non-GAAP EPS of $2.07 beats by $0.15, revenue of $828.57M beats by $7.66M, initiates 2023 guidance [2/6/2023 6:32 AM] |
485.41 |
3.00 (0.62%) |
495.93 |
13.52 (2.80%) |
317.06 - 560.92 |
868,724 |
650,000 |
10,565 |
|
|
01-11-2022 |
PM |
6:30 AM ET (Nov 1) |
IDXX |
IDEXX Laboratories, Inc. |
30,330 |
2.15 |
2.04 |
2.03 |
IDEXX Laboratories Non-GAAP EPS of $2.23 beats by $0.19, revenue of $841.66M beats by $11.66M [11/1/2022 6:34 AM] |
395.21 |
35.53 (9.88%) |
370.00 |
10.32 (2.87%) |
317.06 - 670.92 |
832,999 |
450,000 |
1,408 |
|
|
02-08-2022 |
PM |
6:30 AM ET (Aug 2) |
IDXX |
IDEXX Laboratories, Inc. |
33,060 |
1.56 |
1.55 |
2.34 |
IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M [8/2/2022 6:35 AM] |
400.07 |
1.94 (0.49%) |
387.00 |
-11.13 (-2.80%) |
318.50 - 706.51 |
983,254 |
600,000 |
805 |
|
|
04-05-2022 |
PM |
6:30 AM ET (May 4) |
IDXX |
IDEXX Laboratories |
36,268 |
2.27 |
2.25 |
0.00 |
IDEXX Laboratories Non-GAAP EPS of $2.24 misses by $0.01, revenue of $836.54M in-line [5/4/2022 6:35 AM] |
410.54 |
-25.42 (-5.83%) |
382.00 |
-53.96 (-12.38%) |
381.11 - 706.95 |
1,780,112 |
680,000 |
54,717 |
|
|
02-02-2022 |
PM |
6:30 AM ET (Feb 2) |
IDXX |
IDEXX Laboratories, Inc. |
41,470 |
1.89 |
1.67 |
2.01 |
IDEXX Laboratories GAAP EPS of $1.89 beats by $0.20, revenue of $801M beats by $19.17M; issues full year guidance [2/2/2022 6:33 AM] |
534.76 |
21.25 (4.14%) |
535.00 |
21.49 (4.18%) |
460.36 - 706.95 |
868,219 |
680,000 |
8,351 |
|
|
02-11-2021 |
PM |
6:30 AM ET (Nov 2) |
IDXX |
IDEXX Laboratories, Inc. |
444,450 |
2.03 |
1.88 |
1.69 |
IDEXX Laboratories EPS beats by $0.05, beats on revenue [11/2/2021 6:34 AM] |
627.35 |
-39.13 (-5.87%) |
627.35 |
0.0 (0.00%) |
421.15 - 706.95 |
710,010 |
270,000 |
6,696 |
|
|
30-07-2021 |
PM |
6:30 AM ET (Jul 30) |
IDXX |
IDEXX Laboratories, Inc. |
59,320 |
2.34 |
2.01 |
1.72 |
IDEXX Laboratories EPS beats by $0.23, beats on revenue, raises guidance [7/30/2021 6:34 AM] |
678.86 |
-25.30 (-3.59%) |
674.87 |
-29.29 (-4.16%) |
347.54 - 706.95 |
608,970 |
350,000 |
2,088 |
|
|
04-05-2021 |
PM |
6:30 AM ET (May 4) |
IDXX |
IDEXX Laboratories, Inc. |
47,320 |
2.35 |
1.72 |
1.29 |
IDEXX Laboratories EPS beats by $0.64, beats on revenue; raises FY 2021 outlook [5/4/2021 6:33 AM] |
526.88 |
-23.00 (-4.18%) |
526.88 |
0.0 (0.00%) |
266.00 - 573.99 |
574,887 |
310,000 |
8,372 |
|
|
02-02-2021 |
PM |
6:30 AM ET (Feb 2) |
IDXX |
IDEXX Laboratories, Inc. |
40,830 |
2.01 |
1.43 |
1.04 |
IDEXX Laboratories EPS beats by $0.23, beats on revenue [2/2/2021 6:32 AM] |
507.29 |
14.87 (3.02%) |
501.00 |
8.58 (1.74%) |
168.65 - 522.90 |
591,834 |
403,671 |
2,502 |
|
|
29-10-2020 |
PM |
6:30 AM ET (Oct 29) |
IDXX |
IDEXX Laboratories, Inc. |
37,690 |
1.69 |
1.42 |
1.24 |
IDEXX Laboratories EPS beats by $0.31, beats on revenue [10/29/2020 6:37 AM] |
441.80 |
18.91 (4.47%) |
434.00 |
11.11 (2.63%) |
168.65 - 453.20 |
546,097 |
321,280 |
1,560 |
|
|
31-07-2020 |
PM |
6:30 AM ET (Jul 31) |
IDXX |
IDEXX Laboratories, Inc. |
31,160 |
1.72 |
1.19 |
1.43 |
IDEXX Laboratories EPS beats by $0.54, beats on revenue [7/31/2020 6:32 AM] |
391.38 |
17.28 (4.62%) |
386.19 |
12.09 (3.23%) |
168.65 - 407.86 |
337,269 |
363,397 |
1,710 |
|
|